Positive Effects of Vitamin D Supplementation in Patients Hospitalized for COVID-19: A Randomized, Double-Blind, Placebo-Controlled TrialRandomized Controlled Trial Published on 2022-07-262022-10-05 Journal: Nutrients [Category] COVID19(2023년), SARS, 임상, [키워드] addition administration calcifediol cholecalciferol circulating Clinical improvement Clinical outcome clinical recovery COVID COVID-19 COVID-19 patient COVID-19 severity Day deficiency demonstrated double blind Effect enrolled Hospital stay Hospitalization Hospitalized Mortality Patient patients per day pilot study Placebo Randomized reduced SARS-CoV-2 SARS-CoV-2 positivity significantly significantly lower still hospitalized subject supplemental oxygen the patient the placebo group the WHO therapy treated Vitamin D Vitamin D status Vitamin D supplementation with COVID-19 [DOI] 10.3390/nu14153048 PMC 바로가기 [Article Type] Randomized Controlled Trial
Favipiravir and/or nitazoxanide: a randomized, double-blind, 2×2 design, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE)Favipiravir 및/또는 nitazoxanide: IMSS(FANTAZE)에서 치료를 받는 의료 종사자, 가족 구성원 및 환자를 대상으로 한 COVID-19 조기 치료에 대한 무작위, 이중 맹검, 2x2 설계, 위약 대조 시험Randomized Controlled Trial Published on 2022-07-222022-09-11 Journal: Trials [Category] COVID19(2023년), SARS, 임상, 치료제, [키워드] 1:1 2×2 design absence Admission antimicrobial Antimicrobials Antiviral effect antiviral therapy Antiviral treatment antivirals appear assigned Asymptomatic blinded to treatment combination therapy Comorbidities Comorbidity Controlled trial COVID-19 COVID-19 disease disease double-blind early disease early phase early treatment example Favipiravir followed by Gender Genetic genetic mutation Health high risk Hospitalization Hypothesis in some include individuals Infection Inflammatory Influenza intensive care investigator investigators later phase morbidity and mortality Mutation mutation rate nitazoxanide obesity older patient outcome pandemic participant patients treated pharmacokinetics phase phase IIa Placebo placebo-controlled placebo-controlled clinical trial placebo-controlled trial positive presence or absence Prevent Primary outcome progression protocol randomised randomised controlled trial Randomized receive replicates SARS-CoV-2 secondary Secondary outcomes security Sepsis severe disease smoking status Social Security Stratification symptomatic symptomatic COVID-19 Symptoms tested the disease therapy those with comorbidity Toxicity treatment allocation Trial upper respiratory tract Viral load virus [DOI] 10.1186/s13063-022-06533-0 PMC 바로가기 [Article Type] Randomized Controlled Trial
Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated – VISION Network, 10 States, December 2021-June 2022SARS-CoV-2 Omicron BA.1 및 BA.2/BA.2.12.1 하위 계통이 우세한 기간 동안 면역적격 성인 중 2, 3 및 4 COVID-19 mRNA 백신 용량의 효과 - VISION Network, 10개 주, 2021년 12월 -2022년 6월Article Published on 2022-07-222022-09-11 Journal: Morbidity and Mortality Weekly Report [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI accounted B.1.1.529 BNT162b2 booster dose booster doses Care cause conditions COVID-19 COVID-19 case COVID-19 vaccine Diagnosis dose Effectiveness eligible estimate evade evaluate examined Hospitalization initial median moderate moderate to severe mRNA mRNA COVID-19 vaccine mRNA COVID-19 vaccines mRNA-1273 network omicron Omicron variant pattern Period Pfizer-BioNTech Prevent real-world data receipt receive reduced SARS-CoV-2 SARS-COV-2 infection severe COVID-19 the United State United States vaccination Vaccine-induced immunity variant virus [DOI] 10.15585/mmwr.mm7129e1 PMC 바로가기 [Article Type] Article
Effectiveness and Waning of Protection With Different SARS-CoV-2 Primary and Booster Vaccines During the Delta Pandemic Wave in 2021 in Hungary (HUN-VE 3 Study)헝가리에서 2021년 델타 대유행 기간 동안 다양한 SARS-CoV-2 1차 및 추가 백신을 사용한 보호 효과 및 약화(HUN-VE 3 연구)Article Published on 2022-07-222022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] adjusted age AstraZeneca benefit booster booster dose booster vaccination Booster vaccine booster vaccines Chronic diseases Cohort comparable COVID-19 COVID-19 infection death Delta delta variant Delta wave demonstrated effective Effectiveness examined except for Hospitalization Hungary immunization individual Infection janssen less moderate Moderna Mortality mRNA mRNA vaccine mRNA vaccines offered outcome pandemic Pfizer-BioNTech protection provided Registered restored SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant Sex Sinopharm Sputnik-V study population vaccination Vaccine vaccine effectiveness Vaccines vulnerable population Wave [DOI] 10.3389/fimmu.2022.919408 PMC 바로가기 [Article Type] Article
SARS-CoV-2 epitope-specific CD4 + memory T cell responses across COVID-19 disease severity and antibody durabilityCOVID-19 질병 중증도 및 항체 내구성 전반에 걸친 SARS-CoV-2 에피토프 특이적 CD4 + 기억 T 세포 반응Article Published on 2022-07-222022-09-11 Journal: Science Immunology [Category] COVID19(2023년), SARS, 치료법, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adaptive anti-S antibody antibody Antibody Response Antibody responses Boston CD4 Cell cells circulating conducted controls convalescent individual convalescent individuals coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 disease COVID-19 disease severity demonstrated disease disease control disease course early disease epitope Epitopes First wave follicular function functions greater histocompatibility complex Hospitalization Immunity individual longitudinal study major histocompatibility complex memory memory T nucleocapsid pandemic peptide Population predict proportion recognizing response SARS-CoV-2 SARS-CoV-2 epitope SARS-CoV-2 epitopes seroconverted severe acute respiratory syndrome Coronavirus subset sustained T cell T cells T cells response T helper USA viral clearance virus [DOI] 10.1126/sciimmunol.abl9464 PMC 바로가기 [Article Type] Article
Maternal and neonatal safety outcomes after SAR-CoV-2 vaccination during pregnancy: a systematic review and meta-analysis임신 중 SAR-CoV-2 백신 접종 후 산모 및 신생아 안전성 결과: 체계적인 검토 및 메타 분석Meta-Analysis Published on 2022-07-212022-09-11 Journal: BMC Pregnancy and Childbirth [Category] COVID19(2023년), SARS, 치료기술, [키워드] 95%CI Analysis APGAR score bioRxiv Birth weight case-control studies Cochrane Library conducted controlled trials COVID-19 COVID-19 vaccine database died during pregnancy Evidence Fever FIVE Grey literature hemorrhage hospital Hospitalization inception incidence individual Maternal medRxiv Meta-analysis miscarriage Neonatal Newcastle-Ottawa Scale no effect no statistically significant difference outcome OVID patients postpartum hemorrhage Pregnancy problem problems puerperal puerperal fever Randomized controlled trial Randomized controlled trials risk risk of bia Safety SAR-CoV-2 searched square statistically significant difference systematic review vaccination Vaccine Web of Science [DOI] 10.1186/s12884-022-04884-9 PMC 바로가기 [Article Type] Meta-Analysis
Early identification and severity prediction of acute respiratory infection (ESAR): a study protocol for a randomized controlled trial급성 호흡기 감염(ESAR)의 조기 식별 및 중증도 예측: 무작위 대조 시험을 위한 연구 프로토콜Article Published on 2022-07-202022-09-11 Journal: BMC Infectious Diseases [Category] COVID19(2023년), SARS, 임상, [키워드] 1:1 Acute respiratory infection alarm ARI both groups Clinical diagnosis clinical manifestations clinical trial Consensus Diagnosis diagnostic Efficacy Endpoint enrolled event group Hospitalization in both groups incidence include mechanical ventilation mNGS. multicenter Multiplex PCR non-inferiority Open-label outbreak oxygen participant pathway Patient primary endpoint Prognosis Randomized Randomized controlled trial Randomized controlled trials reached receive resource respiratory infection SARS-CoV-2 secondary Secondary endpoints Severe infection severity Study protocol tested Treatment Treatment outcome Treatment strategies two group two groups [DOI] 10.1186/s12879-022-07552-7 PMC 바로가기 [Article Type] Article
Disseminated mucormycosis in a patient with severe COVID-19 on venovenous extracorporeal membrane oxygenation: A case reportCase report Published on 2022-07-192022-10-05 Journal: IDCases [Category] 바이오마커, [키워드] abdominal wall Antimicrobial therapy Autopsy Case report coronavirus disease COVID-19 COVID-19 associated mucormycosis diagnosed died disseminated mucormycosis extracorporeal membrane oxygenation hemorrhage Hospitalization Invasive fungal infection invasive mucormycosis male membrane Mucormycosis necrotic occurred outbreak Patient patient with COVID-19 patients with COVID-19 receiving Sepsis Septic shock severe COVID-19 severe respiratory failure small intestine steroid suffered the patient was performed [DOI] 10.1016/j.idcr.2022.e01578 [Article Type] Case report
Effectiveness and Cost-Effectiveness of Inactivated Vaccine to Address COVID-19 Pandemic in China: Evidence From Randomized Control Trials and Real-World Studies중국의 코로나19 팬데믹에 대처하기 위한 비활성화 백신의 효과 및 비용 효율성: 무작위 대조 시험 및 실제 연구의 증거Meta-Analysis Published on 2022-07-192022-09-11 Journal: Frontiers in Public Health [Category] 임상, [키워드] 95% CI address Analysis BBIBP-CorV China Chinese clinical trial CNKI combating Control CoronaVac cost-effectiveness COVID-19 COVID-19 infection COVID-19 pandemic COVID-19 vaccination COVID-19 vaccine death determine effective Effectiveness Efficacy Evidence Factor Hospitalization hospitalizations ICU admission ICU admissions immunization inactivated Inactivated COVID-19 vaccine Inactivated vaccine Inactivated Vaccines infections International Medical cost Meta-analysis Perspective prevented Probability RCT Real-world evidence Result robust robustness sensitivity analysis the vaccine vaccination Vaccine vaccine efficacy was performed Web of Science website were used [DOI] 10.3389/fpubh.2022.917732 PMC 바로가기 [Article Type] Meta-Analysis
Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil브라질의 Omicron 기간에 CoronaVac + 이종 BNT162b2 부스터의 보호 기간Article Published on 2022-07-182022-09-11 Journal: Nature Communications [Category] COVID19(2023년), SARS, 변종, 치료기술, [키워드] analysed BNT162b2 booster booster dose Brazil CoronaVac COVID-19 vaccine database death dominance dominant Duration Effectiveness evaluated Heterologous Hospitalization inactivated individual information offered omicron Omicron variant outcome outcomes symptomatic infection tested the SARS-CoV-2 the vaccine vaccinee vaccinees variant [DOI] 10.1038/s41467-022-31839-7 PMC 바로가기 [Article Type] Article